RecruitingNot ApplicableNCT07226284

Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease

The Effects of Vagus Nerve Stimulation on Intrinsic Lower Leg Spinal Motoneuron Excitability in Parkinson's Disease.


Sponsor

University of Minnesota

Enrollment

75 participants

Start Date

Feb 10, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is designed to better understand the mechanisms contributing to impaired activation of leg muscles in people with Parkinson's disease (PD) and to test if stimulation of a nerve at the neck can improve muscle activation, walking and balance.


Eligibility

Min Age: 21 YearsMax Age: 76 Years

Inclusion Criteria6

  • Diagnosis of idiopathic Parkinson's disease,
  • On stable medication for the preceding month and anticipated over the next 3 months,
  • Able to ambulate without the use of an assistive device for more than 50 meters.
  • Control Cohort:
  • Age (± 3 years) and sex distribution matched to the PD cohort,
  • Able to ambulate without the use of an assistive device for more than 50 meters.

Exclusion Criteria15

  • Failure to demonstrate capacity to consent (based on UBACC and/or MacArthur-CR),
  • History of significant neurological disorder (besides PD in the PD group),
  • History of stroke, traumatic brain injury, intracranial aneurysm, intracranial hemorrhage, brain tumor or atypical parkinsonian disorder,
  • Severe orthopedic or other related musculoskeletal pathology that has significant adverse effects on gait,
  • Women who are pregnant or may be pregnant,
  • Insufficient comprehension of the English language,
  • History of substance abuse in past 2 years;
  • Pain at the nVNS treatment site (e.g., dysesthesia, neuralgia, cervicalgia);
  • Lesion (including lymphadenopathy), previous surgery (including carotid endarterectomy or vascular neck surgery) or abnormal anatomy at the stimulation site (open wound, rash, infection, swelling, cut, sore, drug patch, surgical scar\[s\]);
  • Known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g., bruits or history of TIA or stroke), congestive heart failure, known severe coronary artery disease or prior myocardial infarction;
  • Abnormal baseline electrocardiogram (ECG) within the last year (e.g., second or third-degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation);
  • Recent history of uncontrolled high blood pressure, bradycardia, tachycardia, or know recent history orthostatic hypotension;
  • Previous unilateral or bilateral vagotomy;
  • Implanted metal cervical spine hardware, other metallic implants or implantable medical devices such as deep brain stimulator, hearing aid implant, pacemaker, implanted cardioverter defibrillator, cranial aneurysm and/or cranial aneurysm clips, history of facial/orbital/metallic fragments, implanted electronic device, neurostimulator, valve replacements/stents, metallic implants/prostheses) near the stimulation site such as a bone plate or bone screw;
  • History of syncope or seizures (within the last 2 years);

Interventions

DEVICEVagal nerve stimulation

The gammaCore non-invasive vagus nerve stimulator (nVNS) is a hand-held portable device that is used to apply electrical stimulation to the vagus nerve via two electrodes.

OTHERNo intervention

No nVNS is applied in the baseline experiment. Sham nVNS is applied for experiment two


Locations(1)

Movement Disorders Laboratory

Minneapolis, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226284


Related Trials